Clinical Trials Logo

Rheumatologic Disorder clinical trials

View clinical trials related to Rheumatologic Disorder.

Filter by:
  • None
  • Page 1

NCT ID: NCT04702295 Not yet recruiting - Rare Diseases Clinical Trials

ERN ReCONNET Study on COVID-19 Vaccination in Rare and Complex Connective Tissue Disease (VACCINATE)

VACCINATE
Start date: February 2021
Phase:
Study type: Observational

30 months, multicentre, prospective observational study on adult (>18 years) patients with a diagnosis of rare and complex connective tissue diseases (rCTDs) who will be given the vaccine during the period from January 2021 and January 2022. Patients with the following diagnosis will be included: - antiphospholipid syndrome (APS), - Ehlers-Danlos syndrome (EDS), - idiopathic inflammatory myopathies (IIM), - IgG4-related disease (IgG4), - mixed connective tissue disease (MCTD), - relapsing polychondritis (RP), - Sjogren's syndrome (SS), - systemic lupus erythematosus (SLE), - systemic sclerosis (SSc) - undifferentiated connective tissue disease (UCTD)

NCT ID: NCT04244968 Active, not recruiting - Clinical trials for Musculoskeletal Pain

Satisfaction, QoL,Health Status & Clinic Outcomes for Patients Attending MSK Triage Clinics in Rheumatology

Start date: January 22, 2020
Phase:
Study type: Observational

The aim of this study is to measure the impact of musculoskeletal (MSK) complaints on the quality of life and general health of MSK Patients attending MSK triage clinics. The investigators will also record the proposed management options for patients' complaints. This will be achieved by asking patients to complete questionnaires (MSK HQ) at musculoskeletal triage clinic appointment, by undertaking a clinical assessment, by recording the proposed management plan and assessing if patients have follow up appointments for the same complaint in the following year. The investigators will also measure patient satisfaction using VSQ 9 Questionnaire. After a year the investigators will repeat the MSK HQ to assess the longterm impact of MSK Triage appointment on the MSK complaint.

NCT ID: NCT03843658 Not yet recruiting - Clinical trials for Rheumatologic Disorder

Identifying Novel Biomarkers in Early Rheumatology Patients

Start date: March 15, 2019
Phase:
Study type: Observational

Patients new to a rheumatology practice will be asked if they want to consent to their blood sample, medical records, and hand/foot x-rays (with sharp scores) for the analysis and correlation with the diagnosis they will receive from the rheumatologist.

NCT ID: NCT03277703 Completed - Clinical trials for Inflammatory Bowel Diseases

Flu Vaccine Response in Patients on Biologic Therapies

Start date: November 3, 2017
Phase: Phase 2
Study type: Interventional

This proposed study will assess the immunogenicity, safety, and clinical efficacy of an influenza vaccine booster dose strategy in patients with autoimmune diseases who are receiving immunosuppressive therapies. Investigators will compare serologic responses to single versus a booster dose of influenza vaccine in patients with inflammatory bowel disease (IBD- Crohn's Disease or Ulcerative Colitis) or rheumatologic diseases who are receiving immunosuppressive therapies. Subjects will be randomized to receive either one or two doses of influenza vaccination in year #1. In year# 2, all participants will be given two doses of influenza vaccine. Serologic responses will be measured pre and 4-6 weeks post vaccination. This study will also assess the immunogenicity and safety of a booster vaccine strategy in the prevention of influenza-like illness (ILI). Investigators anticipate that booster dose strategy will improve both clinical and serologic responses in this vulnerable population.

NCT ID: NCT03041571 Withdrawn - Cancer Clinical Trials

Impact of Early Implementation of Narrative Medicine Techniques on Patient Centered Attitudes of Medical Students

Start date: March 1, 2017
Phase:
Study type: Observational

A qualitative study assessing the impact of early narrative medicine practice on Medical Honors Program (MHP) students' attitudes regarding patient-centered interactions, through interviewing patients with chronic or life-limiting illnesses to obtain their illness stories. MHP students will develop a patient narrative for the patients interviewed. These narratives will be edited by the patient, and, with the permission of the patients, may be published as a collection of stories.

NCT ID: NCT02678910 Completed - Cancer Clinical Trials

Ovarian Tissue Freezing For Fertility Preservation In Women Facing A Fertility Threatening Medical Diagnosis/Treatment

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this research is to obtain ovarian tissue from female participants who will receive therapy which is expected to result in a loss or impairment of ovarian function and/or infertility and wish to preserve (freeze) ovarian tissue for the purpose of initiating a pregnancy in the future. Removal of the ovary for cryopreservation is an investigational procedure. 100% of the tissue will be used for the participant's future use. There have been 86 pregnancies as a result of frozen ovarian tissue that has been re-implanted back into the pelvis and hormonal function has been restored in individuals for up to 7 years. By doing this study, the investigators hope to learn of how to successfully freeze and thaw ovarian tissue in a manner that permits subsequent use by patients at some point in the future. Participation may also advance our knowledge of how to successfully mature follicles and oocytes (eggs) that are contained in these tissues which may help others in the future.

NCT ID: NCT01685372 Completed - Dialysis Clinical Trials

Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults

Start date: September 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether Fluzone High Dose increases the immune response to the influenza antigens contained in the vaccine compared to standard-dose Fluzone in immunocompromised children and young adults. Safety and efficacy data will also be collected.